Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 in Advanced Hepatocellular Carcinoma
NCT06530251Phase 2Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Sep 2024
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ivonescimab in hepatocellular carcinoma (HCC), sponsored by Akeso, Inc. Primary endpoints: Dose Limiting Toxicities at 3 weeks, Adverse Events and 1 more. Started Sep 2024; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06530251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06530251.